These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22354221)

  • 61. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 62. Selpercatinib Receives Regular Approval for Non-Small Cell Lung Cancer.
    Larkin HD
    JAMA; 2022 Nov; 328(17):1679. PubMed ID: 36318150
    [No Abstract]   [Full Text] [Related]  

  • 63. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
    Herbst RS; Oh Y; Wagle A; Lahn M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Previously unknown side effect of crizotinib emerges.
    Hargrave E
    Pharmacogenomics; 2014 Feb; 15(3):260. PubMed ID: 24783233
    [No Abstract]   [Full Text] [Related]  

  • 65. Food and Drug Administration approval of laboratory tests.
    Allen TC
    Arch Pathol Lab Med; 2013 Jan; 137(1):13-8. PubMed ID: 23276170
    [No Abstract]   [Full Text] [Related]  

  • 66. Histone deacetylase inhibitors in non-small-cell lung cancer.
    Witta S
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S404-6. PubMed ID: 23160335
    [No Abstract]   [Full Text] [Related]  

  • 67. [Discovery and development of alectinib hydrochloride (ALECENSAR capsule 20 mg and 40 mg)
].
    Yoshimura Y; Sakamoto H; Tanaka T; Inagaki N; Uzu M
    Nihon Yakurigaku Zasshi; 2015 Jun; 145(6):318-24. PubMed ID: 26063155
    [No Abstract]   [Full Text] [Related]  

  • 68. Repotrectinib (Augtyro) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2024 Feb; 66(1696):e36-e37. PubMed ID: 38412271
    [No Abstract]   [Full Text] [Related]  

  • 69. Redefining clinical trials: the age of personalized medicine.
    Vaidyanathan G
    Cell; 2012 Mar; 148(6):1079-80. PubMed ID: 22424218
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progress in research on screening and genetics in lung cancer.
    Hirsch FR; Bunn PA
    Lancet Respir Med; 2014 Jan; 2(1):19-21. PubMed ID: 24461890
    [No Abstract]   [Full Text] [Related]  

  • 71. Emerging Options After Progression During Crizotinib Therapy.
    Peters S
    J Clin Oncol; 2016 Mar; 34(7):643-5. PubMed ID: 26712224
    [No Abstract]   [Full Text] [Related]  

  • 72. Phase I trials in oncology: a new era has started.
    Postel-Vinay S; Soria JC
    Ann Oncol; 2015 Jan; 26(1):7-9. PubMed ID: 25361990
    [No Abstract]   [Full Text] [Related]  

  • 73. Matrix metalloproteinase expression in lung cancer.
    Lim M; Jablons DM
    Methods Mol Med; 2003; 74():349-56. PubMed ID: 12415707
    [No Abstract]   [Full Text] [Related]  

  • 74. ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?
    Shaw AT
    Clin Adv Hematol Oncol; 2017 Dec; 15(12):941-945. PubMed ID: 29315286
    [No Abstract]   [Full Text] [Related]  

  • 75. Charge-transfer reaction of 1,4-benzoquinone with crizotinib: spectrophotometric study, computational molecular modeling and use in development of microwell assay for crizotinib.
    Darwish IA; Alshehri JM; Alzoman NZ; Khalil NY; Abdel-Rahman HM
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 Oct; 131():347-54. PubMed ID: 24835938
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted chemotherapy, the medical ecosystem, and the future of American health care.
    Gillick MR
    Perspect Biol Med; 2014; 57(2):268-84. PubMed ID: 25544328
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.
    Xu JL; Wang XZ; Jiang HN; Chen Y; Wang R; Shu YQ
    Chin Med J (Engl); 2020 Oct; 133(20):2495-2497. PubMed ID: 32941237
    [No Abstract]   [Full Text] [Related]  

  • 78. Equal access to innovative therapies and precision cancer care.
    Buzyn A; Blay JY; Hoog-Labouret N; Jimenez M; Nowak F; Deley MC; Pérol D; Cailliot C; Raynaud J; Vassal G
    Nat Rev Clin Oncol; 2016 Jun; 13(6):385-93. PubMed ID: 27000960
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Commitment demanded for lung cancer research.
    McVie G; Thatcher N
    Ann Oncol; 1995 Dec; 6(10):979. PubMed ID: 8750148
    [No Abstract]   [Full Text] [Related]  

  • 80. Practice-Changing Findings.
    Fidler MJ
    Oncology (Williston Park); 2015 Jul; 29(7):502-4. PubMed ID: 26178345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.